Cargando…

Evidence-based cardiovascular magnetic resonance cost-effectiveness calculator for the detection of significant coronary artery disease

BACKGROUND: Although prior reports have evaluated the clinical and cost impacts of cardiovascular magnetic resonance (CMR) for low-to-intermediate-risk patients with suspected significant coronary artery disease (CAD), the cost-effectiveness of CMR compared to relevant comparators remains poorly und...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandya, Ankur, Yu, Yuan-Jui, Ge, Yin, Nagel, Eike, Kwong, Raymond Y., Bakar, Rafidah Abu, Grizzard, John D., Merkler, Alexander E., Ntusi, Ntobeko, Petersen, Steffen E., Rashedi, Nina, Schwitter, Juerg, Selvanayagam, Joseph B., White, James A., Carr, James, Raman, Subha V., Simonetti, Orlando P., Bucciarelli-Ducci, Chiara, Sierra-Galan, Lilia M., Ferrari, Victor A., Bhatia, Mona, Kelle, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734365/
https://www.ncbi.nlm.nih.gov/pubmed/34986851
http://dx.doi.org/10.1186/s12968-021-00833-1
Descripción
Sumario:BACKGROUND: Although prior reports have evaluated the clinical and cost impacts of cardiovascular magnetic resonance (CMR) for low-to-intermediate-risk patients with suspected significant coronary artery disease (CAD), the cost-effectiveness of CMR compared to relevant comparators remains poorly understood. We aimed to summarize the cost-effectiveness literature on CMR for CAD and create a cost-effectiveness calculator, useable worldwide, to approximate the cost-per-quality-adjusted-life-year (QALY) of CMR and relevant comparators with context-specific patient-level and system-level inputs. METHODS: We searched the Tufts Cost-Effectiveness Analysis Registry and PubMed for cost-per-QALY or cost-per-life-year-saved studies of CMR to detect significant CAD. We also developed a linear regression meta-model (CMR Cost-Effectiveness Calculator) based on a larger CMR cost-effectiveness simulation model that can approximate CMR lifetime discount cost, QALY, and cost effectiveness compared to relevant comparators [such as single-photon emission computed tomography (SPECT), coronary computed tomography angiography (CCTA)] or invasive coronary angiography. RESULTS: CMR was cost-effective for evaluation of significant CAD (either health-improving and cost saving or having a cost-per-QALY or cost-per-life-year result lower than the cost-effectiveness threshold) versus its relevant comparator in 10 out of 15 studies, with 3 studies reporting uncertain cost effectiveness, and 2 studies showing CCTA was optimal. Our cost-effectiveness calculator showed that CCTA was not cost-effective in the US compared to CMR when the most recent publications on imaging performance were included in the model. CONCLUSIONS: Based on current world-wide evidence in the literature, CMR usually represents a cost-effective option compared to relevant comparators to assess for significant CAD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12968-021-00833-1.